financial you, today. for Thank you to joining morning. update call I'd Brendan. like thank for and us Good business quarter fourth
As 'XX results. Brendan to we some issued morning, fourth our operating had hope and time and you've year-end this And we review. mentioned, quarter financials
We will XX while last and begin focus some strategy, vision this summarizing corporate of discussing year operational key achievements call months. the our and
also but that testing, will on financials. through some testing worth is our provide landscape over lower to life pass from clinical financials noting laboratory 'XX call that, operating perspective revenue market. first, divisions. and I We me After was Despite the highest CFO, for second it to current lab the quickly let the fiscal greater to the detail, its Bench, in David top Enzo review lower sciences run line year annual COVID revenue due historical will
X% or In $XX.X up fact, fiscal to from Sciences X% million, amounted revenues FX fiscal an Life year 'XX adjusted basis. on 'XX Enzo
average the Our the achieved we focused pipeline, average quarters. highest product across development strategy in the previous drug discussed moving over our as order due years past and year-over-year, to increased X.X% X
overcome we employees level. have and Enzo. my building regarding short company time and the anniversary resources is In I believe next month, Next the past my this blocks at to to X-year assets, here, bring challenges
'XX by strong the today, have whole release year first geopolitical our Enzo in are earlier we at press macroeconomic And we and in the and trends are encouraged quarter mentioned as company. well. As beyond fiscal industry our weathered headwinds a and seeing
very and charting to in of a our of great focused We three forward. strengthening all for have made the Enzo progress going path strategic business the foundation segments regards
the And just investments. importance strategy will we recognize financials in we focused strategy. on I solely commitment to highlight recent like have invest achieved important and return reiterate whereby we that executing where Before I areas described handing to in best the few on quarter, go David, a to go-forward to our last our call off like our would and would our to the milestones, over return
The of high-touch ensure personalized Enzo customer they with succeed labs Physicians is an there but return focus level being that our service lab clinical short-term commercial based as and desire. capital prefer technical of invested. long-term service on they we provide need We support as we, efforts. that choice on on approach, a because is management, at the must the future, our elevated their the and
Enzo through is country. test we lab and local a issue, not to our throughout geographic menu resonates are only Therefore, lab-to-lab and of but need service additions the strengthened to This also the footprint prepared expand partnerships.
be All are manner. ensuring these of in while accomplished profitable that accomplished activities must this a
Enzo Sciences Life a intellectual Enzo future our portfolio our backed has Sciences division, robust the with property. brightest division On Life by
new being Our currently capabilities and transactional well directed will efforts sales which are structure, commercialization our experience enhancing content efforts that Amazon-like launched an website rolled a with at through in is early team as deep 'XX out. as be
LoopRNA have margins higher achieved announced to a of target DNA that that ISH in been leverage RNA, or revenue technology off have designed to probes manufacturing we We of growth and DNA are our achieve AMPIVIEW with through recently products levels. economies specific but that building flat, These our has the scale. already We attractive historically ability a these already RNA interest. RNA, Enzo's growth margins, hybridized are business and we have
products significantly oncology position targeting for market growing way AMPIVIEW, this spatial of the biology HPV expands into in going SARS-CoV-X first and expansion the -- space. With Enzo's pave and detection
sales local executive the We hires. growth. Enzo's quarter for to continued and We talent, of identifying appointed position and working new management team the management the philosophy team share of are developing experienced company by on building in mid-level success. and team members augmented a senior a
within pool and area Enzo an with large talented is strategically a on the New advanced individuals Tri-State industry Island York Long with located of area, experience degrees.
help opportunities Enzo specifically, into its management chapter. on revenue-generating is to growth, focused next Our team more
right partners by with strategic decisions, making core of leveraging We an happy strengths are satisfied our capabilities. environment creating engaging and career employees, the
This adding clinical our technologies To long-term existing points specifically to leverage Biochem our focus market, team end, are A expand to emerging ready platforms offer to success yield physician pain to division, is Diagnostics approach diagnostics on preparing this solve for and industry and which in addressable of poised is individuals Enzo. its will Enzo launch for to future innovations. Enzo laboratories offices. and talented
regulatory can have continue these but by of to success that to Enzo's meet must the It diagnostics resources launch milestones. measured The and platforms. necessary in-house, lines We're platforms we execute. time confident and must hurdles assets be
with demonstrated fully with and and advancement submission we example, filings. GENFLEX, regulatory automated testing for platform, flexible molecular steady For along our EUA pending approval monkeypox path regulatory the other
chlamydia, Health received test this portfolio platform. recently received with another be and These to state HBV will of regulatory diagnostics Enzo New to state, gonorrhea, we tests Earlier with Department on building gaining from year, front. out use confidence the GENFLEX successful the York reputations one our milestones molecular of New trichomonas the State for a laboratory State approval us Enzo's that on platform. of York of market, provide developed approval tests provides us approval confidence federal we on toughest at GENFLEX, the New using More York GENFLEX for
foot growth this expenditure The continued facility in innovations. facilities services, On we Farmingdale, side, will office XXX,XXX support opening earlier the the and expanded laboratory an New of services plans development in announced life York. and laboratory for drug month, product capital clinical sciences
leaders. from on Our Long community launch Enzo's growth Island recent business featured community the updates prospects for perspective business for and event plans on our
On including the banking front, alternatives with we engage advisory our for evaluation services the of strategic continue investment the announced company. previously provide to to bank
We that investors will COVID-XX we as aware are testing are at appropriate, headwinds and environment. unemployment update and to We of management an the facing, whether have this but decline when unfavorable fully report inflationary market nothing time. it's
are can any focused the is storm. the behind on and us this future, However, team manage past we
be would what a headwinds huge COVID in if not I'd acknowledge reduction quarter. sector. us in in testing and we contributor impacted a has that were had Economic remiss challenging our I
as strategic talented that the our efforts team, as have well within We steadfast remain have in company. and potential we our maximizing a we
the future a team commercial focused labs the and is sciences Our us. on bright optimizing has potential at for lab life
We in are prepare in Life for and fiscal lie Enzo particularly opportunities the revenue a our growth year of 'XX, ahead year that enthused Sciences regarding division.
updates During strategy as well progress the with next delivery investors our expect of on regarding go-forward as few our basis. during initiatives a provide to our our information quarters, we about and opportunities calls towards quarterly providing our more
over would fourth our of financials. for like call Mr. David? his detailed to Bench, David turn to our the I review quarter CFO,
